INTRODUCTION {#S1}
============

The concept that food and drugs have common neurobiological and neurogenetic mechanisms has been pioneered first by [@B24] over 25 years ago and introduced into the media and mainstream America by Gold and Avena ([@B19]) and Avena's group ([@B41]).

Research has revealed that obesity results in changes in both behaviors and brain structures quite similar to the changes observed in drug addiction. However, addiction to food is not the cause of all cases of obesity. Can it be assumed that a large group of individuals no longer eat to survive, but rather survive to eat? This article considers the importance of the brain's reward system in food intake the "thrifty gene hypothesis" (survival gene related to famine and fat metabolism) and as such the commonality between food and drug addictions ([@B44]; [@B49]).

Certain overlaps in the brain circuitry activation by food and drug intake suggest that different types of reinforces (natural and artificial) activate a number of the same neural systems ([@B22]; [@B24]; [@B30]; [@B34]; [@B55]; [@B56]). In fact, there are several regions of the brain involved in the reinforcement of both feeding and drug intake ([@B6]; [@B28]; [@B32]; [@B40]), and a number of neurotransmitters, as well as hormones, have been studied in these related brain areas ([@B6]; [@B45]; [@B47]; [@B48]; [@B50]).

An objective of this article is to support these commonality theories, as proposed by [@B3] and [@B9]. In clinical situations, treatment of both food and drug addictions typically appears to present with reciprocal comorbidity and this common comorbidity deserves intensive investigation.

This pilot data from patients attending an outpatient eating disorder program may offer an opportunity for exploration of both inheritable traits and the environmental, genetic expression involved in eating disorders and comorbid drug addiction. Here, we present 50 cases of patients attending an outpatient eating disorder program in North Miami Beach, FL.

CASE PRESENTATIONS {#S2}
==================

Methods {#S2a}
-------

### Procedure {#S2a1}

Observational data from case histories from 50 subjects attending an eating disorder program at "A new Beginning PA," North Miami Beach, FL, and Ocean Breeze Recovery Program, Pompano Beach, FL, have been investigated.

Each patient was interviewed by a clinician using a number of intake instruments including DSM-5 criteria and a structured interview, with duration of at least 1 hr. Each patient was asked for their demographics, their name, age, the location of residence, marital status (single, divorced, married, widowed, in a relationship, or living with a partner), their ethnicity, and their religion to be recorded. A detailed assessment for eating disorder and substance abuse history was made. The eating disorder assessment included the onset of the eating disorder (childhood or adult) and classification/diagnosis of the eating disorder: Compulsive eating (binge eating or grazing), night eating, and bulimia-purging (i.e., self-induced vomiting, laxative abuse, diuretics, overexercising, restricting, or anorexia). The duration of symptoms, frequency of substance (food, sugar, laxatives, and diuretics), and body image (experiencing body dysmorphia) and whether they were stimulated to eat more food after eating sugar and/or flour products were assessed. Family history of eating disorders including any relatives who had, in the past or present, eating disorders, other addictions, and mood disorders was noted. Their current weight and body mass index (BMI), highest weight as an adult if adult onset, or highest weight as a child/adolescent and lowest weight in adulthood, and diets and methods of weight loss or weight gain if attempting to control weight were noted. A history of any bariatric surgeries (gastric bypass, lap band, sleeve) and any suicidal attempts due to weight/food issues was taken. In addition, it is critical to note that the term "eating disorders" included all of the categories stated above including anorexia nervosa.

The substance abuse history had listed every category and specific names of each drug in DSM 5. The instrument was the same as the eating disorders/food addiction history (including all demographics noted above). In addition, a history of suicidal attempts with drugs was taken, and drug overdoses (frequency and names of the drugs used to overdose) and the number of treatment modalities attended, completed and/or left Against Medical Advice were recorded.

### Participants {#S2a2}

The resultant information was self-reported with input from the treatment facility staff. All the subjects were adults, reported ages ranged between 20 and 61 years; other demographic information is listed in Table [1](#T1){ref-type="table"}.

###### 

Demographics of the studied cohort

  Characteristics   *N* (%)                    Total *N* (%)
  ----------------- -------------------------- ---------------
  Gender            30 (60) Males              50 (100)
                    20 (40) Females            
  Race              43 (86) Caucasians         50 (100)
                    6 (12) African-Americans   
                    1 (2) Hispanic             
  Marital status    18 (36) Single             50 (100)
                    12 (24) Married            
                    12 (24) Divorced           
                    2 (4) Separated            
                    6 (12) No response         

### Ethics {#S2a3}

The study procedures were carried out in accordance with the Declaration of Helsinki. The Institutional Review Board of the PATH Foundation NY approved this study concerning obesity research. All subjects were informed about the study and all provided informed consent.

Results {#S2b}
-------

Within the case study group, BMI of 4 subjects was normal (18.5--24.9), BMI of 9 subjects was overweight (25--29.9), and BMI of 37 was obese (30 or greater).

Physical characteristics including height and weight were used to determine the BMI. Other information including a recent food history; drug history; surgical procedures; prior diagnosis; family history of eating disorders; family history of addiction to psychoactive substances, and highest and lowest weights were recorded. The percentages of the characteristics recorded in Table [2](#T2){ref-type="table"} are broken down in the list as follows:--*Food history breakdown:* 3 sugar (6%), 25 flour/sugar (50%), and 22 no response (44%).--*Drug history breakdown:* 8 benzodiazepines (16%), 16 opiates meaning non-heroin opiates and opioids (32%), 14 nicotine (28%), 5 pot meaning marijuana (10%), 9 cocaine (18%), 7 crack meaning crack cocaine (14%), 30 alcohol (60%), 3 crystal meth meaning methamphetamine (6%), 4 heroin (8%), 1 hallucinogens (2%), 3 polysubstance (6%), 1 sedative (2%), 1 hypnotics (2%), 1 mushrooms (2%), and 1 fastest (2%).--*Averages for height:* Males 69.6 in. (176.7 cm), 11 values were missing and females 64.1 in. (162.8 cm), 6 values were missing.--*Averages for weight:* Males 236.4 lb (107.2 kg), 11 values were missing and females 206.2 lb (93.5 kg), 6 values were missing.--*Prior diagnosis breakdown:* 3 eating disorder NOS (6%), 6 bulimia (12%), 6 diabetes (12%), and 35 no response (70%).--*Average BMI:* 33.9 for males and 33.7 for females (see Table [2](#T2){ref-type="table"}).--*Surgical history breakdown:* 8 gastric bypass (16%), 3 lap band (6%), and 39 no response (78%). Family history of eating disorders breakdown: 23 yes (46%) and 27 no response (54%).--*Family drug history breakdown:* 17 yes (34%), 2 no (4%), and 31 no response (62%).

###### 

Results of interviews and clinical instruments for the entire studied cohort

  Pt No.   BMI    Drug history                                                      Family eating disorders   Family drug history   Highest weight lb (kg)/age   Lowest weight lb (kg)/age
  -------- ------ ---------------------------------------------------------------- ------------------------- --------------------- ---------------------------- ---------------------------
  1        36     Opiates, benzodiazepines, alcohol                                           Yes                     No                                        
  2        43.4   Opiates, nicotine                                                           Yes                     Yes                 350 (158.8)/53               200 (90.7)/27
  3        27.4   Alcohol, nicotine, benzodiazepines, pot                                     Yes                     Yes                 210 (95.3)/30                92 (42.7)/20
  4        29.1   Alcohol                                                                     Yes                     Yes                 250 (113.4)/50               160 (72.6)/53
  5        24.8   Alcohol                                                                     Yes                     Yes                 326 (147.9)/22               160 (72.6)/28
  6        30.7   Alcohol, cocaine, heroin, benzodiazepines                                   Yes                     Yes                  230 (104)/15                132 (59.8)/15
  7        38.3   Opiates                                                                     Yes                     No                  299 (135.6)/35               170 (77.1)/24
  8        31.7   Alcohol                                                                     Yes                     Yes                 254 (115.2)/33               145 (65.8)/34
  9        39.1   Alcohol, opiates                                                            Yes                     Yes                  300 (136)/32                165 (74.8)/33
  10       32.3   Opiates                                                                     NR                      NR                                        
  11       36.3   Polysubstance                                                               NR                      NR                                        
  12       31.3   Cocaine                                                                     NR                      NR                                        
  13       29.8   Sedative hypnotics                                                          NR                      NR                                        
  14       27     Alcohol                                                                     NR                      NR                                        
  15       29.9   Alcohol                                                                     NR                      NR                                        
  16       34.4   Alcohol                                                                     NR                      NR                                        
  17       29.1   Alcohol                                                                     NR                      NR                                        
  18       32.8   Polysubstance                                                               NR                      NR                                        
  19       31.1   Alcohol                                                                     NR                      NR                                        
  20       39.6   Alcohol                                                                     NR                      NR                                        
  21       32.6   Cocaine                                                                     NR                      NR                                        
  22       38.4   Opiates                                                                     NR                      NR                                        
  23       31.4   Alcohol                                                                     NR                      NR                                        
  24       28.1   Alcohol                                                                     NR                      NR                                        
  25       36.5   Polysubstance                                                               NR                      NR                                        
  26       34.3   Opiates                                                                     NR                      NR                                        
  27       39.1   Alcohol, benzodiazepines, nicotine, pot                                     Yes                     Yes                 260 (117.9)/28               113 (51.3)/19
  28       30.4   Alcohol, crack, nicotine                                                    NR                      Yes                 210 (95.3)/46                140 (63.5)/37
  29       53.8   Heroin, benzodiazepines, crack, nicotine                                    Yes                     Yes                 290 (131.5)/20               210 (95.3)/22
  30       30.9   Alcohol, cocaine, heroin, benzodiazepines, mushrooms, nicotine              NR                      NR                  235 (106.6)/15               168 (76.2)/18
  31       32.5   Crystal meth, cocaine, alcohol, pot, nicotine                               Yes                     NR                   280 (127)/32                170 (77.1)/32
  32       41.5   Heroin                                                                      Yes                     Yes                 305 (138.3)/16               200 (90.7)/17
  33       33     Alcohol                                                                     NR                      NR                  232 (105.2)/20               175 (79.4)/18
  34       27.5   Alcohol                                                                     Yes                     NR                  303 (137.4)/49               190 (86.2)/50
  35       22.8   Alcohol                                                                     Yes                     Yes                  289 (131)/40                178 (80.7)/60
  36       24.8   Opiates, cocaine, nicotine                                                  Yes                     Yes                 180 (81.6)/17                120 (54.4)/17
  37       22.1   Opiates, crack                                                              Yes                     Yes                 138 (62.6)/19                89 (40.4)/16
  38       35.4   Opiates                                                                     Yes                     NR                   225 (102)/24                140 (63.5)/21
  39       41.5   Alcohol, nicotine                                                           Yes                     NR                   300 (136)/39                185 (83.9)/20
  40       26     Alcohol, benzodiazepines                                                    NR                      NR                  267 (121.1)/40               155 (70.3)/40
  41       33.2   Fastest, nicotine, opiates, cocaine, crack, alcohol                         Yes                     Yes                 250 (113.4)/19               189 (85.7)/17
  42       38.2   Alcohol, crystal meth                                                       Yes                     NR                  230 (104.3)/39               135 (61.2)/25
  43       42.2   Nicotine, cocaine, crack alcohol                                            Yes                     NR                   280 (127)/34                210 (95.3)/18
  44       36     Alcohol                                                                     NR                      NR                   302 (137)/39                218 (98.9)/41
  45       42.7   Opiates, pot, nicotine, hallucinogens                                       NR                      NR                  325 (147.4)/21              230 (104.3)/17
  46       32.8   Alcohol, nicotine                                                           Yes                     NR                  215 (97.5)/45                189 (85.7)/30
  47       32.7   Alcohol, opiates                                                            NR                      Yes                 260 (117.9)/31               195 (88.5)/19
  48       31.5   Benzodiazepines, opiates, nicotine, pot, cocaine, crack                     NR                      NR                  235 (106.6)/22               190 (86.2)/19
  49       34.7   Crystal meth, opiates                                                       NR                      Yes                 270 (122.5)/42               190 (86.2)/22
  50       50.2   Opiates, crack                                                              NR                      NR                                        

*Note*. NR = none reported; opiates = non-heroin opiates and opioids; pot = marijuana; crack = crack cocaine.

In this observational pilot study, any meaningful statistical analysis of the data regarding the family history of SUD was prevented with 62% of the current patients who either did not want to respond or did not know their family history of SUD; however, 17 of 24 cohort families whose drug taking history was available and all of the people in the eating disordered cohort had a comorbid drug history.

DISCUSSION {#S3}
==========

We have reviewed 50 case reports that indicate an explicit relationship between food and drug seeking. The evidence from this pilot experiment on human subjects helps the scientific community to question the requirement for separate treatment methods for two distinct but frequently coexisting abnormal seeking behaviors.

Many articles have examined research developments and current treatments for obesity, including diet and exercise, psychotherapy, surgical interventions, and pharmacotherapies ([@B8]; [@B39]; [@B54]). Overeating may have important neurochemical links to drug abuse, although, less is known about other eating disorders like bulimia and anorexia ([@B27]). There is an evidence that substance use disorder (SUD) has been linked to both bulimia and anorexia nervosa, especially in young women ([@B37]). Some other clinical issues merit attention and provide information that shed light on the commonality concept of food and drug comorbidities. For example, after several years of effective bariatric surgeries, which used to treat obese patients, clinicians now report that some patients are substituting compulsive overeating with other compulsive behaviors. These behaviors involve decreased dopamine (DA) type 2 receptors (DRD2) and include alcoholism, gambling, drugs, compulsive shopping, and exercise ([@B15]; [@B16]). Previously, evidence from psychiatric genetic animal and human studies associating compulsive overeating and other compulsive behaviors was explored to elucidate the process of addiction transfer. Potentially because of neurochemical similarities, overeating and obesity may act protectively by decreasing drug reward ([@B23]). Similar to the process of opiate withdrawal, in animal sugar addiction withdrawal models, imbalances occur in neurotransmitters, such as acetylcholine and DA ([@B4]; [@B19]). In addition, several animal neuroimaging studies have reinforced the link between food craving and drug craving ([@B2]).

Common intricate molecular neurobiological mechanisms related to both food and drug addictions {#S3a}
----------------------------------------------------------------------------------------------

[@B53] reported that in comparison to neutral cues, food and cocaine cues increasingly engaged cerebellum, orbitofrontal, inferior frontal, and premotor cortices and insula and disengaged cuneus and default mode network (DMN). Importantly, these functional magnetic resonance imaging (fMRI) signals were proportional to striatal D2/D3 receptors. Surprisingly, cocaine and food cues also deactivated ventral striatum and hypothalamus suggesting deficiency. Moreover, compared to food cues, cocaine cues produced lower activation in insula and postcentral gyrus, and less deactivation in hypothalamus and DMN regions. In addition, activation in cortical regions and cerebellum increased in proportion to the valence of the cues, and activation to food cues in somatosensory and orbitofrontal cortices also increased in proportion to body mass. As expected, longer exposure to cocaine was associated with lower activation to both cues in occipital cortex and cerebellum, which could reflect the decreases in D2/D3 receptors associated with chronicity ([@B53]).

The authors suggested that these findings show that cocaine cues activate similar, though not identical, pathways to those activated by food cues and that striatal D2/D3 receptors modulate these responses, suggesting that chronic cocaine exposure might influence brain sensitivity not just to drugs but also to food cues ([@B53]).

The term "reward deficiency syndrome" (RDS) was coined to describe the genetic determinants that predict addiction. The predictive value of being a carrier of the DRD2 Taq A1 allele, which may cause future RDS behaviors, was 74% ([@B12]). People with the DRD2 Taq A1 allele carry a reduced number of D2 receptors and, therefore, have reduced DA function. In addition, RDS is polygenetic, which involves a cascade of reward genes. The deficiency concept of DA may not be the only way to gain weight and there is also an evidence for a DA surfeit theory ([@B58]). However, DA function disruptions, in particular, may predispose people to obesity and other addictive disorders. A family history of alcoholism is considered to be a substantial obesity risk factor ([@B43]). Thus, we hypothesize that RDS is the cause of replacing food addiction with other addictive behaviors and may describe this recent phenomenon of addiction transfer that is common following bariatric surgery.

Research into the neuroscience of glucose and cocaine treatments have shown that treatment for both food and psychoactive substance misuse should include DA agonist therapy inducing dopamine release as opposed to present antagonistic DA therapy ([@B1]).

Several molecular and metabolic processes involved in the interaction of dopaminergic system and glucose may provide possible common therapeutic targets for both food and drug addictions. They include --in the mesolimbic structure, the enkephalinergic neurons are found close to the vicinity of glucose receptors;--highly concentrated glucose triggers the calcium channel to activate DA P12 cell release;--a significant connection between blood glucose and cerebrospinal fluid levels of homovanillic acid, the DA metabolite; and--in pharmacological doses, the glucose analog, 2-deoxyglucose (2DG), is related to improved DA yields and produces acute glucoprivation.

Stress-induced cocaine-seeking behavior involves the discharge of neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegmental area (VTA). There is a support for pharmacologically important connections between CRF and orexin-A that are dependent on the oligomerization of orexin OX1 receptors (OX1R) and CRF1 receptor (CRF1R). CRF1R--OX1R heteromers are like the channels of an adverse crosstalk between orexin-A and CRF as exhibited in rat VTA and transfected cells, where it considerably regulates dendritic DA discharge. The cocaine target 1 receptor (1R) also links with the CRF1R--OX1R heteromer. Cocaine binding to the 1R--CRF1R--OX1R complex supports a long-standing disturbance of the orexin-A--CRF negative crosstalk. It is within this mechanism that cocaine sensitizes VTA cells to the stimulatory effects of both CRF and orexin-A, hence offering a mechanism by which stress produces cocaine seeking ([@B42]). The RDS model of etiology holds very well for a variety of chemical (drugs and food) and behavioral seeking that can result in addiction.

Dopamine function deregulation is a significant cause of addictive behaviors, like drug, alcohol, and food addictions. Dopamine and other reward neurotransmitters are also a part of a largely dispersed neural network responsible for regulation of eating behavior, affecting both homeostatic and hedonic mechanisms ([@B7]; [@B35]). Considering this, the dopaminergic and opioidergic mechanisms are especially involved in palatable food modulation, and opioid antagonists weaken drug cravings and palatable food appetite. Therefore, palatable food cravings could be contemplated as a type of DA-opioid-related addiction. Though there are at least five dopaminergic receptors, the D1 and D2 have been most associated with reward according to the research ([@B35]).

Interestingly, [@B38] suggested that post-ingestive mechanisms occurring from nutrients in the gut could impact food consumption and behavioral conditioning. The physiological processes essential to these mechanisms are multifaceted and are thought to join in mesolimbic DA signaling to translate post-ingestive sensing of nutrients that have a reinforcement reward value.

Currently, there are three chief families of opioid receptors (μ, κ, and δ), of which the μ-receptors are most involved in reward. The cases that show common phenotype between food and drug addictions suggest a common therapeutic target ([@B29]). They found that low µ-opiate receptor availability results in increased feeding behavior. Similarly, dopaminergic agonists reduce appetite ([@B18]) while DA antagonists, especially at D2 loci, increase ingestive behavior ([@B36]). Have we hatched the common phenotype egg and should we consider common treatment for these two seemingly diverse substances?

Obese versus lean humans have less striatal D2 receptors and show fewer striatal reactions to palatable food intake ([@B52]). These findings align with the idea that those who have hypofunctioning reward circuitry are inclined to overeat, to satisfy a reward deficit. Also, decreases in striatal response to food intake forecasts weight gain in the future for those at genetic risk for lowered signaling of DA-based reward circuitry, particularly in adolescents ([@B52]). There is also an alternate possibility that a surfeit of DA may also cause weight gain ([@B51]). However, animal studies specify that palatable food intake causes downregulation of D2 receptors, decreased D2 sensitivity, and reduced reward sensitivity, suggesting that overeating may denote diminished striatal responsivity. [@B51] and [@B52] examined whether or not overeating causes decreased striatal responsivity to palatable food intake in humans utilizing repeated measures of fMRI. Outcomes specified that females who gained weight during a 6-month period showed a decline in striatal response to palatable food ingestion compared to females who had stable weight. Together, these results imply that low sensitivity to reward heightens the risk for overeating and additionally, overeating may diminish the responsivity of reward circuitry in a feed-forward manner, specifically in DRD2 A1 allele carriers ([@B14]).

Neuroimaging studies have revealed that psychoactive substances, palatable foods, and anticipated behaviors, such as gambling and sex, affect brain structures that activate reward circuitry and may not be unidirectional. Psychoactive substances boost DA signaling and sensitize mesolimbic mechanisms that have been developed to modulate the incentive salience of reward processing ([@B33]). Drugs of abuse are willingly self-administered. Either directly or indirectly, they heighten the dopaminergic synaptic function in the nucleus accumbens and fuel brain reward circuitry functioning (creating the "high" that drug users pursue). Though initially thought to determine the setting of hedonic tone, the functions of dopaminergic circuitry are now understood to be more intricate, coding for attention, reward expectancy, disconfirmation of reward expectancy, and incentive motivation. Elevated stress levels, along with dopaminergic gene polymorphisms and additional neurotransmitter genetic variants, may have an aggregate effect on the susceptibility to both food and drug addictions involving epigenetic effects ([@B57]). Recently, [@B5] clearly showed that dopaminergic tone at rest is reduced in attention-deficit/hyperactivity disorder. This work suggests that subjects presenting with comorbid aberrant seeking behavior may share a common rubric displaying a hypodopaminergic trait/state.

Food and drug comorbidities observed -- 50 case series {#S3b}
------------------------------------------------------

Understanding these common intricate molecular neurobiological mechanisms related to both food and drug addictions is underscored by this 50 case series, showing that 100% of patients attending an eating disorder clinic had previous psychoactive substance misuse history both in the present and in the past. However, due to unknown factors like adoption, the information on family history needs to be more intensely investigated in this cohort or a larger cohort in future studies. However, showing that 48% of the patients did have a family history of eating disorders seems important and provides some information regarding genetic inheritability. Our finding of 34% having a known family history of psychoactive substance misuse also seems to be important in terms of psychoactive substance addiction inheritability.

Limitations {#S3c}
-----------

This is a small observational pilot study with only demographic information and without meaningful statistics to support the main theme of this article. A much larger cohort with non-eating disorder controls must be evaluated in future studies. Also, we did not characterize the type of psychoactive substance misuse in terms of severity, which is important in terms of genetic commonality ([@B19]; [@B24]; [@B53]; [@B55]). We are indeed encouraged, however, since all 50 subjects who entered an eating disorder clinic had comorbid SUD or at least aberrant seeking behavior history.

Future perspectives {#S3d}
-------------------

This study found that subjects who entered an eating disorder clinic had comorbid substance-use-seeking behavior. Many theories supported by scientific neurochemical and genetic studies offer sound evidence that food addiction and psychoactive drug addiction are similar ([@B21]) in spite of arguments to counter this notion ([@B59]). Genetic and epigenetic impairments of the brain reward circuitry, which cause hypodopaminergic functioning, define RDS ([@B8]). RDS involves neurotransmitter exchanges and produces abnormal craving behaviors. Animal and human fMRI studies reinforce the hypothesis that several similar brain circuits are disturbed during drug addiction and obesity, which involves DA-modulated reward circuits in habitual eating ([@B10]).

Recognizing the role of DNA and polymorphic links to brain reward circuitry has steered us to an innovative treatment for addiction, which is important to psychiatry in the genomics era. This approach may offer support to those who suffer from RDS. Studies have indicated that assessing established reward gene and polymorphism panels permits the stratification of genetic risk for RDS. The panel named the "Genetic Addiction Risk Score (GARS™)" is a diagnostic instrument for genetic predispositions to RDS. Clinical groups using this test would have the advantage of being able to detect from an early age of those at risk for both food and drug addiction liabilities ([@B11]; [@B20]).

The current failure of DA D2 agonists in clinical use is due to chronic downregulation of the D2 receptors' targets. Less potent D2 agonists that may upregulate D2 receptors have had some clinical success ([@B13]). Thus, approaches aimed at DA function improvements, rather than treatments that block DA function may better treat food- and drug-seeking behavior. The significant role that genes play in reward dependence and associated behaviors including food and drug addictions is emphasized by the role of DA.

[@B45] reported that processed foods, high in fat and glucose, were most frequently associated with addictive-like eating behaviors. Moreover, processing was a large, positive predictor for whether a food was associated with problematic, addictive-like eating behaviors. In their model, fat and glucose were large, positive predictors of problematic food ratings. This underscores the need to restrict these foods during recovery from both food and drug addictions.

CONCLUSION {#S4}
==========

Based on this, pilot case series finding focus on natural activation of dopaminergic reward circuitry as a type of common therapy may certainly be parsimonious ([@B17]; [@B25]; [@B26]; [@B31]). While this study may not answer the definitive question as to the true relationship between food and drugs of abuse, it does extend the view of a commonality rather than non-commonality. Additional research in this regard is warranted especially further neuroimaging studies to unravel the current mysteries involved in eating disorder like anorexia and bulimia, and any links to common mechanisms to drug-seeking behavior.
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